Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Eduard E. Holdener"'
Autor:
Peter Dalquen, Rudolf Joss, Pierre Alberto, Serge Leyvraz, Hans-Jörg Senn, Franco Cavalli, Eduard E. Holdener, P. Siegenthaler, C. Ludwig, K. Bürki, Rolf A. Stahel, Ernst Schatzmann
Publikováno v:
Cancer. 65:2426-2434
From 1984 through 1986, 205 patients with non-small cell lung cancer were entered into a group-wide trial of the Swiss Group for Clinical Cancer Research (SAKK). This trial evaluated the combination of mitomycin (8 mg/m2 intravenously [IV] on day 1),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cee8035c194853e3f5816ff67f5831fc
https://doi.org/10.1002/1097-0142(19900601)65:11<2426::aid-cncr2820651104>3.0.co
https://doi.org/10.1002/1097-0142(19900601)65:11<2426::aid-cncr2820651104>3.0.co
Publikováno v:
International Journal of Cancer. 50:868-870
Five partial responses were seen in 23 patients with metastatic renal-cell carcinoma (MRCC) receiving interferon-alpha 2a (IFN)+prednisone (P). Four of 24 subsequent patients responded to IFN+P (combined response rate 19%). The median response durati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a9eb75ef72b7287071c37fc90aecb45
https://doi.org/10.1002/ijc.2910500606
https://doi.org/10.1002/ijc.2910500606
Autor:
Wim W. ten Bokkel Huinink, Otto Klepp, Cristina Sessa, C. Ludwig, Eduard E. Holdener, Michel Clavel, Genevieve Decoster, Herbert M. Pinedo, Georgette Renard, P. Siegenthaler
Publikováno v:
European journal of cancer (Oxford, England : 1990). (3)
Anaxirone, a rationally synthesised triepoxide derivative, was given to 46 patients with metastatic colorectal cancer. Good risk patients received 800 mg/m(2) as a rapid intravenous injection every 4 weeks, whereas poor risk patients received 650 mg/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25dba36c0178d232ed672641b7a5555f
https://pubmed.ncbi.nlm.nih.gov/8204365
https://pubmed.ncbi.nlm.nih.gov/8204365
Autor:
Eduard E. Holdener, Werner Bollag
Publikováno v:
Current opinion in oncology. 5(6)
This review highlights recent advances in understanding the mode of action of retinoids at the level of molecular and cellular biology in relation to the new clinical results achieved with retinoids in various malignancies. All-trans-retinoic acid ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::624e2d73e53df7f087ae4ff653ae7ede
https://pubmed.ncbi.nlm.nih.gov/8305540
https://pubmed.ncbi.nlm.nih.gov/8305540
Autor:
Eduard E. Holdener, Christian Ludwig, Georgette Renard, Genevieve Decoster, Herbert M. Pinedo, Wim W. ten Bokkel Huinink
Publikováno v:
Investigational New Drugs. 6:227-230
Menogaril, a new semisynthetic anthracycline antibiotic, was administered to 35 patients with advanced colorectal cancer. The drug was infused over 2 hr at a dose of 160 mg/sqm or 200 mg/sqm repeated every 4 weeks. Twenty-seven patients were evaluabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ee174a8494c9ffe03b3d3e7a83dedf6
https://doi.org/10.1007/bf00175404
https://doi.org/10.1007/bf00175404
Autor:
J. Renard, Heine H. Hansen, U. Bruntsch, Eduard E. Holdener, Herbert M. Pinedo, Hans Høst, Marcel Rozencweig, Franco Cavalli
Publikováno v:
Investigational New Drugs. 3:63-66
Epirubicin, a stereoisomer of doxorubicin with suggested lower potential for cardiotoxicity in experimental animal tumor systems, was studied in a disease-oriented phase II trial in patients with advanced colorectal cancer. The drug was given as a di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2f553ecd7295f50823905710ce45520
https://doi.org/10.1007/bf00176826
https://doi.org/10.1007/bf00176826
Autor:
Eduard E. Holdener, Pierre Alberto, Victor Hofmann, P. Siegenthaler, Reto Abele, Susanna Kaplan, Ryssel Hj, Diethelm Hartmann, Franco Cavalli
Publikováno v:
Journal of Clinical Oncology. 1:750-754
Doxifluridine, a new fluoropyrimidine derivative, was tested in a cooperative phase II trial by the Swiss Group for Clinical Cancer Research in advanced measurable colorectal cancer. The drug was given in a five consecutive day schedule by a bolus in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7d526ddc005836720c5c634fdcf4ddd
https://doi.org/10.1200/jco.1983.1.12.750
https://doi.org/10.1200/jco.1983.1.12.750